Financial Disclosures

The CONY Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of CONY participants. In doing so, the CONY Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The CONY Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content. Program members who fail to provide financial disclosures are not permitted to participate in the development of educational content.

Presenters

The CONY Congress considers financial relationships to create actual conflicts of interest when Presenters or their immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Presenter) have both a financial relationship with a commercial interest and the opportunity to affect the policy of the CONY Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias.

All presenters of CME content should familiarize themselves with the policy of the CONY Congress of CME based on the CME provider of the Congress – the EACCME (http://admin.uems.net/uploadedfiles/174.pdf).

All CONY Faculty presenting CME are required to disclose to the activity audience the following information prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The CONY Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

NOTE: All presenters are required to report financial disclosures, using the codes below. An individual's financial disclosures for the 7th CONY Congress meeting are listed in this Section.

CONY Financial Disclosure Codes

Category None Consultant	Code N C	Description No financial relationships Consultant fee, paid advisory boards Advisor fees for attending a meeting (for the past 1 year)
Employee	Ε	Employed by a commercial entity
Lecture fees	L	Lecture fees (honoraria), travel fees or reimbursements when Speaking at the invitation of a commercial entity (for the past 1 year)
Equity owner	0	Equity ownership/stock options or publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial products or providers of commercial services
Patents / Royalty	Р	Patents and/or royalties that might be viewed as creating a potential conflict of interest
Grant support	S	Grant support for the past 1 year (all sources) and all sources Used for this project if this form is an update for a specific talk or publication with no time limitation

Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

Susan Abushakra, USA	C, S, L Novartis
E Elan Pharmaceuticals	C, S, L Ono Pharmaceuticals
	C, S, L Receptos
Kadriye Agan, Turkey	C, S, L Roche
NNo financial interest	C, S, L Sanofi Aventis
	C, S, L Teva Neuroscience
Conk Akhastansi Turkov	C, S, L
Cenk Akbostanci, Turkey	C, 3, L wyeui
L Abbott	
L Abdi Ibrahim	Leontino Battistin, Italy
L Allergan	N No financial interest
C, L Bohringer Ingelheim	
L Gen İlaç	Betul Baykan, Turkey
L Generica	N No financial interest
L GSK	
L Medtronic	Nerses Bebek, Turkey
C, L Lundbeck	N No financial interest
L Novartis	iv No illiancial interest
L INOVALUS	Fatour Books Task.
	Ettore Beghi, Italy
Gulsen Akman-Demir, Turkey	S ALS Assoc. (USA)
C, L Novartis	C Eisai
C, L Bayer Schering	S GSK
L Teva	S Italian Inst. of Health
L Gen İlaç	S Italian Pharma Public Agency (AIFA)
L Merck Serono	S Janssen Cilag
	S Kedrion Pharma Co.
Frank Andrasik, USA	S Sanofi Aventis
N No financial interest	
N NO IIIIaliciai liiterest	S Sigma-TAU
	L UCB-Pharma
Angelo Antonini, Italy	C Viropharma
N No financial interest	
	Elinor Ben-Menachem, Sweden
Messoud Ashina, Denmark	C Bial
C Alder Biopharmaceuticals, Inc.	C BioControl
C Alder Biopharmaceuticals, Inc. C, L Allergan A/S	C BioControl C, L Eisai
C, L Allergan A/S	
	C, L Eisai C, L Janssen-Cilag
C, L Allergan A/S C, L Allergan Norden	C, L Eisai C, L Janssen-Cilag C, L Lundbeck
C, L Allergan A/S C, L Allergan Norden Ovidiu Bajenaru, Romania	C, L Janssen-Cilag C, L Lundbeck C, L UCB
C, L Allergan A/S C, L Allergan Norden Ovidiu Bajenaru, Romania C, L Bayer-Schering	C, L Eisai C, L Janssen-Cilag C, L Lundbeck
C, L	C, L Janssen-Cilag C, L Lundbeck C, L UCB S Västra Götalands
C, L	C, L Janssen-Cilag C, L Lundbeck C, L UCB S Västra Götalands Yitshal Berner, Israel
C, L	C, L Janssen-Cilag C, L Lundbeck C, L UCB S Västra Götalands
C, L	C, L Janssen-Cilag C, L Lundbeck C, L UCB S Västra Götalands Yitshal Berner, Israel No financial interest
C, L	C, L
C, L	C, L Janssen-Cilag C, L Lundbeck C, L UCB S Västra Götalands Yitshal Berner, Israel No financial interest
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L
C, L	C, L

Natan Bornstein, Israel	Mark Freedman, Canada
CEver NeuroPharma	C, S, L Bayer Healthcare
C Brainsgate Ltd	S Genzyme
L Pfizer Israel	C, L Actelion
L Bayer Israel	C, L Celgene
L Rafa Laboratories Ltd	C, L EMD Canada
L Kaia Laboratories Ltu	C, L Biogen Idec
Michael Brainin Austria	
Michael Brainin, Austria	C, L Glycominds
N No financial interest	C, L
Malfana Duilak Camana	C, L Sanofi-Aventis
Wolfgang Brück, Germany	C, L Teva Canada Innovation
L Bayer Pharma	Dantalainan Ciannalan anta-
S, L Biogen Idec	Panteleimon Giannakopoulos,
C, LGenzyme	Switzerland
L Merck Serono	N No financial interest
C, S, L Novartis	All 6 111 D :
L Sanofi	Alla Guekht, Russia
C, S, L Teva Pharma	C Takeda
Roger Bullock, UK	Hakan Gurvit, Turkey
N No financial interest	N No financial interest
Ken Butcher, Canada	Lea Grinberg, USA
C, L Bayer Canada	N No financial interest
C BMS/Pfizer Alliance	
C, S, L Boeringher Ingelheim Canada	Hans L. Hamburger, The Netherlands
L Boeringher Ingelheim South Africa	N No financial interest
Abhijit Chaudhuri, Canada	Hans-Peter Hartung, Germany
N No financial interest	C Biogen Idec
	C Genzyme
Laszlo Csiba, Hungary	C Hoffmann-LaRoche
N	C Merck Serono
	C Novartis
Nese Dericioglu , Turkey	
N No financial interest	Eva Havrdova, Czech Republic
	C, S, EBiogen Idec
George Ebers, UK	C, E Genzyme
N No financial interest	C, E Merck Serono
	C, E Novartis
Lars Edvinsson, Sweden	C, E Teva
N	5,
	Christopher Hawkes, UK
Wagih El Masry, UK	N No financial interest
N No financial interest	
	Wolf-Dieter Heiss, Germany
Bulent Elibol, Turkey	N No financial interest
C, L Lundbeck (Turkey)	
C, L Novartis (Turkey)	Martin Holtkamp, Germany
C, L Boehringer Ingelheim (Turkey)	N No financial interest
C, L Abdi Ibrahim Drug Cmp.	
L Gen İlaç Drug Cmp.	Volker Homberg, Germany
,p.	N No financial interest
Ozlem Erden Aki, Turkey	
N	Rivka Inzelberg, Israel
	N No financial interest
Gokhan Erkol, Turkey	
N	Kurt Jellinger, Austria
	N No financial interest
Cristian Falup-Pecurariu, Romania	
LUCB	Orhun Kantarci, Turkey
	N No financial interest

Zaza Katsarava , Germany N No financial interest	Kristina Müller, Germany N No financial interest
Mark Keegan, USA	Dafin Muresanu, Romania
L AAN	N No financial interest
C Bristol-Myers Squibb S Caridian BCT	Picardo Nitrini Brazil
L CMSC	Ricardo Nitrini, Brazil C, L Novartis
E Mayo Clinic	L Moksha8
LNIH/NIAI	
C Novartis	John W. Norris
	N No financial interest
Vasilis Kimiskidis, Greece	
L GSK L UCB	Marco Onofrj, Italy
L UCB	N No financial interest
Jera Kruja, Turkey	Ozcan Ozdemir, Turkey
N No financial interest	N
Gülnihal Kutlu, Turkey	Aynur Özge , Turkey
N No financial interest	N No financial interest
Kursad Kutluk, Turkey	Cigdem Özkara, Turkey
L Boeringher Ingelheim	N No financial interest
Jose Miguel Lainez, Spain	Jacqueline Palace, UK
L Allergan	N
C Autonomic Technologies	
S Boston Scientific	Lakshmi Ranganathan, India
C Colucid	N No financial interest
S Medtronic	AL B
L MSD	Allargan
S Nosoira L TerumoBCT	L Allergan C, L IMPAX
L Terumober	C MAP
Kennedy Lees, UK	C, L Nautilus Neurosciences
N No financial interest	C Winston
	C, L Zogenix
David Leppert, Switzerland	
O, E Roche	Ivan Rektor, Czech Republic
Jacek Losy, Poland	N No financial interest
N No financial interest	Michael Ropacki, USA
TV	E Janssen Research & Development,
Albert Ludolph, Germany	LLC
N No financial interest	
	Magnhild Sandberg-Wollheim,
Umaiorubahan Meenakshisundaram,	Sweden
India C Allergan India	C Actelion C Almirall
C Allergali filula	C Bayer Health Care
Ron Milo, Israel	C, L Merck Serono
S Biogen Idec	C Novartis
L Medison	C Roche
S, L Novartis	
	Jack Schim, USA
Dimos Mitsikostas, Greece	L Allergan
C Bayer	Pohort Shaniro USA
L Lily C Merck Serono	Robert Shapiro, USA C Map Pharmaceuticals
C Novartis	5 Plup i narmaceuticais
C Teva	

Ashfaq Shuaib, Canada	Oguz Tanridag, Turkey
S AGA Medical	N No financial interest
S, L Asubio Pharmaceuticals	
C, S, L Bayer	William Theodore, USA
C, L Bohringer Ingelheim	N No financial interest
C, S Brainsgate	
C CoAxia	Maria Trojano, Italy
C dPharm	C, L Biogen Idec
C, S Lundbeck	C, LNovartis
L Merck Trust	L Merck Serono
C, L Pfizer	
C, S Photothera	Daniel Truong, USA
C Sanofi Aventis	S Abbott/Abbvie Pharmaceuticals S Adamas Pharmaceuticals
Aksel Siva, Turkey	S Allergan Pharmaceuticals
C Allergan	S GlaxoSmithKline
C Biogen Idec	S, L Ipsen Pharmaceuticals
C Novartis	S Merz Pharmaceuticals
S TUBITAK SBAG	S Neurocrine Pharmaceuticals
L Merck Serono	S Schering Plough
L Bayer Schering	S UCB Biosciences
Luiza Spiru, Romania	Nevzat Uzuner, Turkey
N No financial interest	N No financial interest
David Spence, Canada	Teus Van Laar, The Netherlands
C Bristol-Meyers Squibb	C Abbott
S Pfizer	C, L Britannia
L Merck	L Medtronic
L Bohringer Ingelheim	C, L Novartis
gege	S,
Michael Sperling, USA	Laszlo Vecsei, Hungary
C Upsher Smith	N No financial interest
C	N
C Upsher Smith	N No financial interest Patrick Vermersch, France C Almirall
C Upsher Smith Venkatesan Srinivasan, India	N No financial interest Patrick Vermersch, France C Almirall C, S, L Bayer
C	N No financial interest Patrick Vermersch, France C Almirall C, S, L Bayer C, S, L Biogen Idec
C	N No financial interest Patrick Vermersch, France C Almirall C, S, L Bayer C, S, L Biogen Idec L GSK
C	N
C	N
C	N
C	N
C	N
C	N
C	Patrick Vermersch, France C
Venkatesan Srinivasan, India N	Patrick Vermersch, France C
C	Patrick Vermersch, France C
C	Patrick Vermersch, France C
C	Patrick Vermersch, France C